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1Northern Ireland Molecular Pathology Laboratory, Centre for Cancer Research and Cell Biology, Queen’s University Belfast,
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119074 Singapore; 3Diagnostic Molecular Oncology Centre, Department of Pathology, National University Health System, Yong
Loo Lin School of Medicine, National University of Singapore, Singapore and 4Tissue Pathology, Belfast Health and Social Care
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In the context of solid tumours, the evolution of cancer therapies to more targeted and nuanced approaches has led to the
impetus for personalised medicine. The targets for these therapies are largely based on the driving genetic mutations of the
tumours. To track these multiple driving mutations the use of next generation sequencing (NGS) coupled with a morphomolecular
approach to tumours, has the potential to deliver on the promises of personalised medicine. A review of NGS and its application
in a universal healthcare (UHC) setting is undertaken as the technology has a wide appeal and utility in diagnostic, clinical trial and
research paradigms. Furthermore, we suggest that these can be accommodated with a unified integromic approach. Challenges
remain in bringing NGS to routine clinical use and these include validation, handling of the large amounts of information flow and
production of a clinically useful report. These challenges are particularly acute in the setting of UHC where tests are not
reimbursed and there are finite resources available. It is our opinion that the challenges faced in applying NGS in a UHC setting
are surmountable and we outline our approach for its routine application in diagnostic, clinical trial and research paradigms.
The future of modern medicine will be dictated by new discoveries
in the molecular basis of disease, new technological advances and
the accessibility to these developments that healthcare systems
provide for individual patients. Indeed, the question of next
generation sequencing (NGS) in routine diagnostics epitomises
these aspects; a new technology delivering novel DNA-based
discoveries in routine diagnostics, which can be applied within
those healthcare systems making it affordable for routine use.
There are excellent examples of NGS validations in the literature
(Frampton et al, 2013; Cheng et al, 2015) coming from well-
resourced, reimbursement-based healthcare systems. However,
many countries have at least a partly or wholly universal healthcare
(UHC) system (Figure 1) and the application of NGS technology
has some common challenges but also further distinct considera-
tions in this environment.
An all-encompassing definition of UHC can be difficult.
A reasonable working definition is all required healthcare which
is free at the point of care. However, due to the rapid nature of
progress particularly in the area of molecular-based medicine the
line between what is necessary and what is required is obscured.
The proliferation of genetic technology and in particular
sequencing technology means that many patients are familiar with
and proactive in seeking genetic information regarding their
disease. Many oncologists will have the experience of patients
requesting genomic sequencing of their tumour. This can be
accomplished in private healthcare or if ones insurance coverage
allows for reimbursement. In contrast, in a UHC environment,
resources are finite and therefore it is important to ensure that
cancer patients are provided with at the very least all the molecular
information regarding their tumour that can affect its manage-
ment. It has also been shown that prognostic signatures can
provide confidence for the patient in management and be of
economic benefit such as oncotype Dx (Holt et al, 2013).
At present the molecular information required for standard-of-
care management can be achieved predominantly through single-
gene tests. However, we are at a tipping point with more targeted
therapies coming online and immune-checkpoint modulation a
real option in combatting solid tumours. These interventions
require more detailed information than ever regarding the
molecular composition of tumours and it is arguable that this
information can be provided in a more efficient and timely fashion
utilising NGS technology as a ‘one-stop-shop’ for all the currently
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targetable driver mutations in a tumour (Souilmi et al, 2015). In
addition, given that tumour heterogeneity drives the evolution of a
cancer the identification of potential targets which may become
relevant following late recurrences or first line treatment failure are
important for future management of the patient.
It is clear that the age of personalised medicine is here, with
many cancer care pathways requiring both histological-based
diagnosis and molecular pathology mutational analysis of the
tumour (Friedman et al, 2015). Frequent allelic variants of
actionable target mutations are reliably detected by clinically
applied low-throughput technologies. However, analysis of 4742
tumour-normal matched controls across 21 tumours types revealed
over 200 cancer-related genes many having clinically relevant
frequencies of 2–20% (Lawrence et al, 2014). Furthermore, down-
sampling analysis has estimated that increasing the sample size will
reveal more clinically relevant mutations. Clearly, attempting to
describe these mutations using single-gene technology is not
feasible (Lawrence et al, 2014).
There are a number of paradigms where NGS can be applied
(Table 1). The most significant is its role in clinical diagnostics where
it can examine all standard of care, actionable mutations simulta-
neously from low-quality formalin-fixed paraffin-embedded (FFPE)-
derived DNA. These specimens can include different types including
fine needle aspirations (smears and/or cell blocks), biopsies and
resections with many differences in their pre-analytical processing.
The second paradigm is a clinical trial where it can provide
comprehensive data regarding potential actionable mutations.
Finally, NGS can be used in the research paradigm by rapidly
identifying candidate biomarkers. We would argue that these
paradigms need a holistic, patient-centred and affordable approach
for the appropriate healthcare system, ideally in an integrated
molecular pathology environment (Salto-Tellez et al, 2014).
MODELS FOR APPLICATION OF NGS IN A UHC SETTING
It may seem self evident that centralisation of molecular pathology
services is required to make them viable in a UHC setting, however,
there are still many hospitals currently carrying out molecular tests,
usually with single-gene technology, on small numbers of samples in
UHC settings which obviously raises costs. Given the current capital
expense of NGS platforms, specialised personnel required and
bioinformatics infrastructure needed, these costs could only be
justified in a centralised laboratory (Figure 2). In this model there
are logistical issues regarding sample transport and ensuring
standardisation of pre-analytical factors. Moreover, if the hospital is
a cancer centre and does not have molecular diagnostics there may be
a disconnect with the MDTs where feedback on results may be
required. This can be easily addressed through teleconferencing.
The expense of NGS platforms and capital equipment will likely
come down in the future. With the proliferation of this technology a
centralised model may evolve over time to a more decentralised
model with several cancer centres serving regional populations
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Figure 1. Global expenditure on health related to GDP and the efficacy of the global UHC environment. We have highlighted countries with a
private healthcare spend of o40% as an index for UHC (WHO and Bloomberg).
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carrying out the tests while sending their results to a central
bioinformatics core. One might suggest that such bioinformatics
cores could be superseded by cloud-based computing (Souilmi et al,
2015). However, this raises significant issues regarding sensitive
health data travelling across jurisdictions for storage or analysis.
Future directions for the evolution of NGS in solid tumour
testing include its use to analyse so-called ‘liquid biopsies’ which
involves the analysis of cell free DNA from the patient’s serum.
The use of serial liquid biopsies has been shown to be useful in
monitoring disease progression/treatment failure. In particular this
has been shown in lung cancer studies where new driver mutations
were identified in patients with a previous T790M mutation (Chia
et al, 2016) Patient preference for less invasive procedures and
the difficulties in obtaining serial tissue biopsies means that the
increased volume of liquid biopsies may contribute to making the
scalable NGS more cost-effective for UHC-based institutions.
NGS CLINICAL APPLICATIONS
The chief considerations as to whether NGS will be successfully
applied to routine diagnostics are clinical utility and cost (Aronson,
2015). Even in these early days of genomic-based oncology, where
numbers of actionable mutations are still relatively modest, the test
result must relate to an evidence-based management decision.
The majority of management decisions for cancer patients in a UHC
environment are made at vital MDTs, with oncology, pathology,
radiology and surgery input amongst others. At present the binary
form of information regarding mutations (mutant/wild type) makes
the addition of molecular information to the MDT environment
equivalent to prognostic immunohistochemistry such as HER2
receptor analysis. However, as molecular pathologists we are aware
that such information is rarely binary and requires setting of
thresholds and other elements which may be obscured in the
bioinformatics that produce a result for the oncologist. Therefore, it
is vital to curate the data in the reports using up-to-date clinical trial
information and to be able to interpret these results at MDTs.
Indeed, the curation of the NGS data into a meaningful
diagnostic report is challenging, particularly for large gene panels,
due to several degrees of ‘clinical relevance’ within the information
provided. When crafting these reports, it can be unclear whether
a specific mutation activates or inactivates the gene, or if it
engenders sensitivity to specific therapies, or how therapies should
be prioritised where there are multiple genomic alterations.
Consequently, mutations are identified and actioned as part of
(a) standard-of-care pathways, (b) clinical trial enrolment and
(c) ‘no option’ patients without significant evidence for a targeted
therapy. Indeed, one could argue that in these early days of
genomic diagnostics reporting we are ‘managing levels of genomic
(un)certainty’. Therefore, communicating the level of evidence/
confidence in these results needs to be illuminated for clinicians.
This approach is epitomised in the model of Dienstmann et al
(2014), where the genomic results are organised, into levels of
clinical applicability, as ‘treatment recommendation’, ‘clinical trial
eligibility’ or ‘observe /talk to an expert’.
Within a UHC system it is clear that a centralised database
for annotation and curation of reports is vitally important.
Such a system allows finite resources to be used economically
including information technology infrastructure and bioinfor-
matics as well as molecular pathology expertise. Furthermore, it
would allow standard reports with clear recommendations to be
provided to clinicians. Similarly to our radiology colleagues’ change
to digital pathology, such a change in histopathology would require
up-front investment in IT and personnel by a UHC system.
An individual institution’s capacity to engage in personalised
medicine depends on the defined standard of care in a given
country, the institutional access of patients to clinical trials,
and the openness of institutional ethical review boards to
Table 1. List of paradigms where NGS can be used
NGS paradigm
Parameter Research Clinical trials Diagnostics
Clinical samples Best possible High quality Variable
Analysis Discovery; as broad as possible Broad; some targeting of clinically actionable genes Targeted; only genes with clinical utility
Confirmation of all results Selected results Not required Not cost-effective
Reporting of results Selected reporting and interpretation;
Whatever is significant for the authors
Selected reporting; whatever is appropriate to enrol
patients in the clinical trial or direct their therapy
Wide reporting; whatever may help
the patient in the present and
potentially in the future
Abbreviation: NGS, next generation sequencing.
Most feasible current model for NGS in a UHC system
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Figure 2. Diagrammatic version of our suggested models for the
evolution of NGS in a UHC environment.
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allow therapeutic intervention, based solely on biological
observation. This is accentuated in the 58 countries, as of 2009,
with UHC (Stuckler et al, 2010). In such systems, there is
frequently a contrast between the approach of healthcare
administrators managing finite resources, who must apply
strict criteria regarding the ‘rules of engagement’ for therapeutics
and consequently for diagnostics, and academic healthcare
professionals who wish to offer a patient-specific best option and
derive as much as possible for future patients. Micro-costing has
shown that for lung cancer in a reimbursement model the cost of a
5–50 gene panel is $578 to $908 (Sabatini et al, 2016). Interestingly,
there is an estimated decrease in costs compared with single-gene
testing when clinical trial participation is factored in, where
investigational drugs do not cost much. When this is factored in
there is a modest cost increase due to increased use of targeted
therapies overall (Sabatini et al, 2016). Never before has the gap
between what is possible and what is affordable in patient
diagnostics and treatment been so obvious in modern medicine.
However, exceptions to this dynamic exist. In Canada, a credible
private pathway is available which provides reimbursable testing at
a national level led by global experts in the field such as Dr. Samuel
Aparicio (http://contextualgenomics.com). In contrast, the Ger-
man Network for Genomic Medicine (NGM) in lung cancer is a
healthcare network providing NGS-based multiplex genotyping for
all inoperable lung cancer patients (Kostenko et al, 2015). Since
German reimbursable procedures do not include NGS-based
multiplex genotyping, NGM has successfully started a nationwide,
pilot-project establishing a flat rate reimbursement model for NGS
in Germany, a model transferrable to other tumour types. In the
UK, the 100 000 genome project run by Genomics England (http://
www.genomicsengland.co.uk/the-100000-genomes-project/) aims
to generate substantial whole genome sequencing data from different
cancer types, including rarer forms and, at the same time, shape the
testing landscape where no model for diagnostic testing currently
exists. The longevity of these initiatives remains to be seen.
PRE-ANALYTICAL FACTORS FOR THE CLINICAL USE OF NGS
Many of the pre-analytical factors which affect the performance of
NGS are common regardless of the health system encountered due
to the commonality of FFPE. Within a UHC system the use of
consistent guidelines is important to provide high-quality DNA
from such specimens for testing (Lindeman et al, 2013; Gargis et al,
2016). Moreover, within UHC systems the use of such standardised
guidelines and tissue pathways, fixation times and a morphomo-
lecular approach would all contribute to high-quality DNA.
Moreover the use of cytological samples can provide higher
concentrations of tumour DNA. In histological specimens we
advocate the use of a guiding H&E slide along with a
morphomolecular approach (Salto-Tellez et al, 2014). Many
laboratories will be familiar with providing scrolls of FFPE tissue
for molecular analysis to private laboratories for analysis. However,
without expert review the relative amount of tumour or, indeed
whether tumour is present at all, cannot be guaranteed. Low or no
tumour concentration in a sample increases the chance of test failure
and misinterpretation of wild-type results, that is, too low a
concentration of tumour may result in too weak a mutation signal to
be picked up above the wild type ‘noise’. One caveat regarding all
tests and tumour sampling is tumour molecular heterogeneity which
may reflect the site of the tumour sampling. The use of a
morphomolecular approach, allows tumour morphology to inform
sampling and indeed clonal areas may be identified on histology
which can be sampled and tested separately to help guide treatment.
Where appropriate cytological samples may be recommended to
clinicians regarding molecular testing of a tumour and this
provides useful genetic material for testing once the tumour
concentration is at least 20% and the specimen is sufficiently
diagnostically advanced (Salto-Tellez, 2015). For example lung
cytology cases which are equivocal for squamous or adenocarci-
noma would skew EGFR results if mistyped and cause unnecessary
expense. Indeed, the combination of rapid on site assessment, the
lack of fixation effect and the potential use of direct smears in
addition to cell blocks makes cytology specimens very attractive for
NGS testing as described and utilised by the MD Andersen group
(Roy-Chowdhuri and Stewart, 2016).
CHOICE OF GENE PANEL FOR NGS
Presuming that most laboratories will adopt a pragmatic NGS-
targeted approach, detecting hotspot mutations, there are several
variables that determine the choice of panel and its associated
costs:
1. Design of the gene panel: a number of possible designs are
outlined below (Figure 3).
Class 1 design: basic actionable mutations, up to 10–15 genes
hotspots and larger gene regions. This will hold hotspot
mutations considered routine, for genes such as KRAS (colorectal
and lung), NRAS (colorectal and melanoma), BRAF (melanoma
and colorectal), EGFR (lung), KIT (gastrointestinal stromal tumour
(GIST) and melanoma), PDGFRA (GIST and melanoma) and
larger gene regions such as BRCA1 and 2 (ovarian). PIK3CA and
TP53 could be added to this hotspot list, as well as some of the
myeloproliferative related mutations such as JAK2, CALR and
MPL.
Class 2 design: broad, clinically relevant, up to 50 genes. This
design will include those in Class 1 and, in addition, mutations that
allow oncologists to enrol patients in clinical trials supported by
the individual institution. Therefore, these are very much hospital-
dependent. They may include mutations of AKT1 or ESR1 (breast
cancer), PTEN (prostate cancer) or MET in several cancer types
(Dietel et al, 2015).
Class 3 design: tumour comprehensive, up to 150 genes. This is
a cancer-specific design for translational research, comprising all
relevant mutations relating to the cancer’s biology.
Class 4 design: human cancer comprehensive, up to 400
genes. This includes all cancer-relevant genes.
2. The volume of testing: presuming a TAT of 1–2 weeks and a
minimum of 1 run per week, an accurate assessment of the
laboratory’s average working volume throughout the year is vital
for allocation of resources and choice of testing platform. Clinical
Class 4
Human cancer
comprehensive200–400
50–200
20–50
6–12
Class 3
Tumour
comprehensive
Class 2
Clinically relevant
Class 1
Actionable
mutations Diagnostics Discovery
Clinical
trials
Figure 3. Choice of gene panel based on the paradigm being
investigated by NGS.
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factors impacting on this such as introduction of new surgical
services must be anticipated through a management structure.
3. The size of the runs: tightly related to the previous point.
A chip with capacity for 20 cases may be more affordable per case
than a chip of 12 samples. However, if a lab has 9–12 cases per
week, and runs a chip per week for TAT purposes, then a 12
sample chip may be more cost-effective (Figure 4).
4. The technology: different platforms may need different up-
front costs, and many have different running costs.
5. The minimum DNA requirement: Diagnostic practices with
resection specimens are likely to yield significant DNA content per
sample, and thus the minimum DNA concentration threshold
necessary to run the test is easily achieved. However, in small
biopsy or cytology samples total DNA may be limiting, with larger
numbers of cases deemed inadequate. This is an important
consideration for overall laboratory budgeting, because the number
of fails and need to maintain accreditation for single-gene
orthogonal tests can make the overall cost of NGS testing
significantly more expensive.
6. The availability of a clinical reporting bioinformatics system:
discussed with validation below.
VALIDATION
The validation of NGS includes pre-analytical, nucleic acid
preparation, sequencing and bioinformatics. Validation of NGS
needs to examine analytical sensitivity, specificity, accuracy and
precision as well as validating for minimum sequence coverage and
downstream validation of bioinformatics pipelines. With the levels
of validation required it is important to set standard parameters in
advance. In particular, choices of instrument and bioinformatics
approach are important considerations. Crucially pre-analytics must
be considered as discussed above. New embedding materials and
processing of specimens particularly for auto-embedding units need
to be validated to ensure no loss of mutant signal. Interestingly, the
authors have personal experience of gel-based embedding material
interfering with downstream molecular analysis.
Accreditation for molecular tests should be achievable by a
professional and competent laboratory (Aziz et al, 2015). Low-
throughput assays have a straightforward validation/verification
process with the precise variants having matched, characterised
reference material. For NGS, however, validating every variant
within the target DNA is not feasible (Salto-Tellez et al, 2014). No
such reference material exists to accommodate all the variants that
could be examined using NGS. Reference materials, in the form of
pooled cell lines, have proven helpful in providing strength to
NGS validation although are imperfect (Frampton et al, 2013).
A pragmatic approach is to validate the main clinically relevant
targets initially and then validate the less frequent mutations in an
ongoing continuous manner as they are detected. This requires
the use of orthogonal reference standard methods in addition to
the NGS testing which may make costs prohibitive. Moreover, the
gold-standard method, Sanger sequencing, has a lower sensitivity
than NGS and will miss lower frequency mutations.
The most successful validations of diagnostic NGS thus far have
been carried out using single-platform approaches with tumour
samples or pooled cell lines which have well-characterised
molecular aberrations. From our own experience there has been
a tendency to have local variations in sample type (scrolls vs
morphomolecular slides vs fresh samples), platform type and
bioinformatics tools which inhibits collaborative validations. We
propose that cross centre collaborative validations represent the
best model for carrying out efficient NGS validations within a
UHC system (Figure 5). These would take the form of specific
molecular pathology centres having strict provisions regarding
agreed instrumentation and protocols, including bioinformatics, to
carry out benchmarking validations of various mutations and
mutation types. This would subsequently be followed by valida-
tions of other mutations carried out separately in the different
centres and then extrapolated between the centres. Regular internal
‘calibration’ sets of tumours would be routinely analysed to ensure
adequate quality control.
Some of the limitations of NGS include its ability to detect
different mutation types, in particular large insertions/deletions,
which may be suboptimally recognised in this setting and
these would need careful validation to ensure adequate sensitivity.
Practical solutions have been described with validations of
NGS in the literature (Frampton et al, 2013; McCourt et al,
2013; Cottrell et al, 2014; Cheng et al, 2015; Wang et al, 2016). It is
interesting to note that the most detailed validations have occurred
in the US where the health system is predominantly a private
Cost per sample = fixed cost per sample(*) +
(*) DNA extraction/quantification/QC library
preparation/quantification/QC library barcoding
cost per run (**)
n = samples per run
(**) Sequencing reagents + chip/flow cell
TAT=1 week
12 samples week 1 One chip week 1
13 samples week 2
+
+
One/two chips week 2
Bioinformatic pipeline
Bioinformatic pipeline
Report
to
clinician
Report
to
clinician
Figure 4. Estimation of costs associated with NGS runs linked to testing volume.
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concern. Frameworks in this health setting have been published
from several sources including the Association for Molecular
Pathology, and the College of American Pathologists. To date, the
ability to demonstrate validation of NGS in a UHC setting has been
limited and may require the innovations described above to be
successful.
The most comprehensive attempts to validate NGS in clinical
practice include the Foundation Medicine Group validation
(Frampton et al, 2013) and the Memorial Sloan Kettering
integrated mutation profiling of actionable cancer targets (MSK-
IMPACT) validation (Cheng et al, 2015). Foundation examined
287 cancer-related gene exons and introns from 19 genes
frequently rearranged in solid tumours. They validated their
process with cell lines mimicking a range of mutant allele
frequency percentages (Frampton et al, 2013). A similar cell line
approach was used to validate for single-nucleotide variants
(SNVs) in the Washington University cancer mutation profiling
NGS assay (McCourt et al, 2013). In addition, within the
Foundation validation, indels were validated by spiking tumour
pools with known somatic indel variants. Copy number alterations
were validated using tumours with various amplifications and
homozygous deletions matched with normal cell lines in a range of
tumour concentrations (Frampton et al, 2013). The MSK-IMPACT
approach analysed 341 cancer genes (Cheng et al, 2015).
Validation in this case was carried out using 284 tumour DNA
samples and 75 matched controls. The tumour samples had
previously been genotyped/sequenced using alternative methods
and had SNVs or indels in 47 exons of 19 genes with 393 known
variants detected.
Outside of an environment where there is insurance reimburse-
ment for tests and significant endowment/direct investment, the
cost of validation is also a sensible concern. For NGS with modest
scope (o20 genes), validation of all possible variations including
all clinical hotspots, extraction protocols, sample types and a
bioinformatics pipeline could cost close to d60 000 in the UK
setting for consumables alone. Furthermore, in the UK, where cost
effectiveness of new standards of care is driven by organisations
like the National Institute for health and Care Effectiveness
(NICE), the dialectic between what is necessary to test, what is
desirable to test in the clinical trial and academic context, and
what would be useful to inform future therapeutic decisions
without current clinical trial evidence, is difficult to manage.
However, it is important to consider that current analysis for point
mutations of clinical relevance may already cost d200–300 per case
to the National Health Service, and hence NGS solutions able to
provide a test within that boundary would be cost neutral to UHC
systems.
INFORMATION FLOW WITH NGS
All three aspects of information flow for NGS must be validated,
these include (1) the bioinformatics pipeline, (2) the compiling and
communication of the clinical report, and (3) the integration of
(1) and (2) with the laboratory information system (LIS). Increasing
amounts of information at each level raises a number of issues for
service delivery including adequately skilled personnel and infra-
structure issues with associated costs of storage and processing
power. A hybrid facility, as suggested by the ‘Belfast model’
(Salto-Tellez et al, 2014), combines the skill sets of an academic
bioinformatics department within a clinical environment to produce
a cost-effective bioinformatics pipeline with clinical utility and
appropriate TATs for application in a UHC setting (Oliver et al,
2015). It is clear from the ISO15189 standard for accreditation that
the same rigorous validation is required for the bioinformatics
pipeline and any change results in re-validation, although the raw
FASTQ data can be used to condense this process considerably.
Data generated following the initial reads, sequence alignment
and variant calling within the pipeline must be assimilated into a
meaningful clinical report requiring interpretation of the bioinfor-
matics by the reporting team. The role of clinical scientist within
this context is key to bridge the bioinformatics to the clinical
report. In departments with an integrated model consisting of
molecular diagnostics, clinical trial work and biomarker discovery,
a dedicated bioinformatician is required. Communicating these
results to clinicians is a critical role for the reporting team who
Step 1: design
Several centres
Same NGS platform
Same approach pre-analytica factors
Same Bioinformatics pipeline
Step 2: induction
Known standards shared for benchmarking
validation studies
Maybe tumours/cell lines or both
Cover the most common variants
Step 3: extrapolation
Individual centres further validate
with other mutations
Results communicated between centres
Extrapolate findings between centres
Step 4: maintenance
Standards sets shared between centres
to maintain quality within a QA system
Figure 5. A model for NGS collaborative validations as suggested for a UHC environment. We have proposed to use this system within the UK
NHS for collaborative validations between centres. This is a non-centralised, non-hierarchical system across centres of excellence.
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need to incorporate this information into the care pathway in a
clinically useful TAT. They will rely on annotation databases which
are accurate and constantly updated/curated (Dienstmann et al,
2014). However, as highlighted in a germline setting, evidence-
based annotations can be inaccurate in a third of cases (Bell et al,
2011). To ensure optimal interpretation of the tests, consistent
bottom line diagnoses must be used and it may be argued that the
reporting team members should partake in multidisciplinary team
meetings to aid dissemination of the results.
Workflow management for single-gene assays can be achieved
using spreadsheet databases. However, this is not scalable for NGS
testing. It will be a necessity in the future that the (LIS) will require
integration with the bioinformatics pipeline. Furthermore, con-
solidation of an LIS within a UHC setting must take into account
molecular testing from pathology, clinical genetics, microbiology
and haematology.
CLINICAL TRIALS AND NGS
Perhaps the most obvious application for NGS is in clinical trials.
Tumour heterogeneity gives cancer the ability to evolve and be
driven by resistance clones developing in response to the selective
pressures of treatment (Enriquez-Navas et al, 2015). Tracking this
complex biology cannot be done with low-throughput technologies
and NGS is necessary to allow for full tumour taxonomy within the
timeframe of a clinical trial.
Trial designs which aim to incorporate molecular stratification of
patients include umbrella, basket and adaptive. Umbrella trials are
merely an extension of the current dogma in clinical trials with solid
tumours characterised in the first instance by histology and then
with additional limited mutation parameters which allow substra-
tification of tumours. Although only an incremental step, it has
proven fruitful in lung cancer with EGFR analysis, colorectal
cancer with N/KRAS and melanoma with BRAF. Basket trial
design allows mutation characteristics of a tumour, independent of
site and other histological factors to be used to select patients.
However, this must be done with a biological rationale (Sleijfer et al,
2013), as highlighted by KIT mutations in GISTs (Nakahara
et al, 1998).
In our opinion the clinical trial design which has best
incorporated molecular pathology and which would be ideal for
use in an NGS environment is the adaptive design. An example of
the use of this design in a UHC system has been the Biomarker-
integrated Approach of Targeted Therapy for Lung Cancer
Elimination (BATTLE) trials which utilised a statistical adaptive
design (Kim et al, 2011) allowing the trial to be more ethical and
effective. The National Lung Matrix Trial being carried out within
the NHS in the UK seeks to enhance the number of molecular
targets which may used in non-small cell lung cancer (Middleton
et al, 2015). The aim is to identify known molecular targets found
at low frequencies. Similar to the BATTLE design this study utilises
a Bayesian adaptive design which allows for more power for low
frequency mutations where recruiting sufficient patients in a
traditional clinical trial would not be possible. It may be anticipated
that single-gene testing will have a limited role in future clinical
trials and by combining NGS diagnostics and clinical trial patients
overall costs may be reduced in UHC as already described in a
reimbursement model (Sabatini et al, 2016).
CONCLUSIONS
In these early days of genomic medicine, how cancer practitioners
learn to generate, manage and act upon genomic information may
dictate the speed with which we help our cancer patients live longer
and better lives. Thus, even at a time in which cancer healthcare
costs are consistently increasing, this is not the moment to have a
‘common denominator’ approach to genomic testing. NGS
technology is bringing high-quality analysis at an affordable cost,
and it may be strategically sound for UHC systems to accept
that an increase in budgets associated with genomics testing,
whilst we learn to apply it clinically, will be a great long-term
investment.
The ideal model for provision of molecular diagnostics in UHC
systems remains controversial but is at the heart of how we wish to
deliver NGS for diagnostics. The Canadian private model, the
unified model for NGS lung cancer testing in Germany, or the lack
of a defined model for commissioning of molecular diagnostics
currently favoured in most of the UK, are currently available.
Significant centralisation, ensuring concentration of technical
skills, resources and economy of scale will make for the most
cost-efficient framework for NGS diagnostics in the future.
Genes and HUGO Nomenclature:
NRAS neuroblastoma RAS viral (v-ras) oncogene
homolog
BRAF B-Raf proto-oncogene, serine/threonine kinase
EGFR epidermal growth factor receptor
KIT KIT proto-oncogene receptor tyrosine kinase
PDGFRA platelet-derived growth factor receptor alpha
BRCA breast cancer 1
BRCA2 breast cancer 2
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase
catalytic subunit alpha
TP53 tumour protein p53
JAK2 Janus kinase 2
CALR calreticulin
MPL MPL proto-oncogene, thrombopoietin receptor
AKT1 v-akt murine thymoma viral oncogene
homolog 1
ESR1 oestrogen receptor 1
PTEN phosphatase and tensin homolog
MET MET proto-oncogene, receptor tyrosine kinase
FAT4 FAT atypical cadherin 4
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